2013 || Aarkstore.in || Pharmaceutical Pricing and Reimbursement in Oncology - Payer

1

Introduction Aarkstore Enterprise
Our comprehensive and wide range of databank in
the field of Market Research Report provides
exclusive, pioneering and innovative service to
our report buyers. Our high-quality databank
comprises of company profiles, strategy review,
company report, industry reports, company
financials, industry research, SWOT analysis, and
so on Aarkstore.com is in the forefront as it
is enriched with comprehensive informative and
interactive search features. One can browse to
have ample access of beyond 2.5 lakh business
industry reports.
2
Category

• Pharmaceuticals Healthcare Market Research
  Reports http//www.aarkstore.co
  m/market-sector-reports/Pharmaceuticals--Healthca
  re-7.html

3
Report
2013 Pharmaceutical Pricing and Reimbursement
in Oncology - Payer Aarkstore.in
http//www.aarkstore.in/Pharmaceutical-Pricing-
and-Reimbursement-in-Oncology-Payer.html
4
Request Sample
http//www.aarkstore.com/Report/SampleRequest.asp?
RptId216600
5
Summary

• GBI Research, leading business intelligence
  provider, has released its latest research
  report, entitled Pharmaceutical Pricing and
  Reimbursement in Oncology - Payer Pressure to
  Justify Premium Pricing of Novel Agents, Pushing
  Companies to Risk-Sharing Modalities. It
  provides a comprehensive overview of the
  healthcare system, and the pricing and
  reimbursement processes in the top seven
  countries of the world, with a detailed analysis
  of the different regulatory mechanisms used in
  these countries. The report closely scrutinizes
  the major pharmaceutical changes and
  oncology-related pricing and reimbursement in
  these countries in the recent past and their
  impact in the near future. The countries analyzed
  in the report are the US, the top five European
  countries of the UK, France, Italy, Germany and
  Spain and Japan.
  
  More

6
Table of Contents

• 1.1 List of Tables 61.2 List of Figures
  72 Pricing and Reimbursement in Oncology -
  Introduction 83 Pricing and Reimbursement in
  Oncology - Overview 93.1 Development of Oncology
  Drugs 123.2 Market Access and the Role of Health
  Economics in Cancer Drugs 133.2.1 Regulation of
  Cancer Drugs in Europe 133.2.2 Hospital Budgets
  and Patient Access to Drugs 133.2.3 Payers
  Managing Influx of New Therapies through
  Innovative Strategies 143.2.4 Risk Sharing
  Agreements in the US Vis-à-vis Europe 15More

7
Latest Reports
http//www.aarkstore.com/publishers/GBI-Research
-85.html  Pharmaceutical Pricing and
Reimbursement in Oncology - Payer Pressure to
Justify Premium Pricing of Novel Agents, Pushing
Companies to Risk-Sharing ModalitiesPediatric
Vaccines Market to 2017- Strategic Focus on
Partnering as Licensing and Co-Development
Accounted for 69 of Deal-Making Activity from
2004-2011Manufacturing of Solid Dosage Forms -
Transformation in Manufacturing Concepts and
Expanding Contract Manufacturers Production
Capacity May Force Regulatory Bodies to Re-Design
Guidelines on Quality Standards Emerging
Pharmaceutical Market in South Africa to 2017 -
Proposed Introduction of New Drug Regulatory
Agency (SAHPRA) to Accelerate Drug Registration
Process
8
(No Transcript)
9
Contact us
For More details about above other Reports
please contact Lavanya Aarkstore.com Contact
Marketing team Mob.No.918149852585 Email
Customersupport_at_aarkstore.com
Sonali_at_aarkstore.comURL http//www.aarkstore.com
http//aarkstore.in/